Daito Pharmaceutical Co., Ltd.
Notice of Treasury Stock Acquisition and Cancellation
As part of the medium-term management plan capital policy, the Company will acquire treasury stock (up to 1,250,000 shares, 4.4%) and cancel those shares on May 31, 2027. Acquisition period: 2026/10/15–2027/5/21; total amount upper limit: 2,000 million yen.
Key Figures
- Total number of treasury shares to be acquired: 1,250,000 shares (upper limit)
- Total acquisition amount for treasury shares: 2,000 million yen (upper limit)
- Total number of shares to be cancelled: 1,250,000 shares (planned)
AI要約
Details of Capital Policy Implementation
As part of the medium-term management plan, the Company will carry out treasury stock acquisition and cancellation. The acquisition is up to 1,250,000 shares (representing 4.4% of the total number of issued shares), with a total amount upper limit of 2,000 million yen. The acquisition period is from October 15, 2026 to May 21, 2027, and the trading method is the Tokyo Stock Exchange on-floor market. The Company plans to cancel the same number of shares, 1,250,000 shares, with the cancellation date set as May 31, 2027.
Impact and Future Outlook
Through the acquisition and cancellation of treasury stock, the Company intends to enhance shareholder returns and capital efficiency. As of September 30, 2026, the current treasury stock holding is slightly under 500,000 shares. Through this acquisition and cancellation, the Company aims to suppress dilution and maximize shareholder value.
Daito Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
